PCN143 - Trends in Hospitalization Lenght of Stay and Costs in Patients with Peripheral T-Cell Lymphoma (PTCL): Analysis of US National In-Patient Data for 2015

Abstract

To examine trends in hospital length of stay and total costs in patients with peripheral T-cell lymphoma. The latest available 2015 National Inpatient Sample (NIS) data set of hospital admissions from the Healthcare Cost and Utilization Project was utilized in order to determine the number of hospital admissions for patients with PTCL (identified by ICD-9 for Q1-Q3 and ICD-10 codes for Q4). The LOS and costs were compared by payer type, race and age groups. Based on our inclusion criteria we found 555 admissions, representing 0.006% of all hospitalizations. The mean age was 58.2 years (SD: 16.07, Median 60 years). The overall mean LOS was 9.27 days (SD: 10.26, Median 6 days). Majority of the hospitalizations were in patients age 60+ (52%), followed by age 45-59 (31%). Mean (SD) LOS by age: 18-45: 10.36 days (SD: 12.9, n= 65), 45-59: 9.82 days (SD: 9.94, n= 130), 60+: 8.3 days (SD: 8.42, n= 215). The mean LOS by payer: Medicare: 8.33 days (SD: 8.4), Medicaid: 10.67 days (SD: 14.67), Private: 9.21 days (SD: 8.97). The overall mean charges were $104,546 (SD: $160172). The mean costs by age group were 18-45: $116689 (SD: $176348), 45-59: $121640 (SD: $177315), 60+: $83229 (SD: $112386). The mean costs by payer type were: Medicare: $87864 (SD: $117720), Medicaid: $127052 (SD: $221859), Private: $108091 (SD: $161065). There were no significant differences in LOS and charges by race or gender. Patients with PTCL incur some costs for public and private payers due to the need for hospitalization. While costs are moderate, the long length of stay poses significant burden on hospitals. Newer more effective treatments are needed to lower the LOS for hospitals.